AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32964773 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended services
Number of subjects: 56
Study 33979096 — intervention group
Group type: EXPERIMENTAL
Intervention: VCP immunoreactivity in lesional psoriatic sections
Number of subjects: 25
Study 33979096 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermal VCP H-score
Number of subjects: 25
Study 33979096 — intervention group
Group type: EXPERIMENTAL
Intervention: VCP expression in the dermis
Number of subjects: 25
Study 33979096 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher VCP in the dermis
Number of subjects: 25
Study 33376746 — intervention group
Group type: EXPERIMENTAL
Intervention: AE‐IPF risk prediction model based on history of occupational exposure, diabetes mellitus (DM), essential hypertension (EH), and diffusion capacity for carbon monoxide (DLCO)% predicted.
Number of subjects: 110
Study 33376746 — intervention group
Group type: EXPERIMENTAL
Intervention: AE‐IPF risk prediction model
Number of subjects: 110
Study 36192617 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 5 mg
Number of subjects: 123
Study 36192617 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg
Number of subjects: 123
Study 36192617 — intervention group
Group type: COMPARATOR
Intervention: Control (no added treatment)
Number of subjects: 123
Study 33779741 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet search for health information
Number of subjects: 5000
Study 34251536 — intervention group
Group type: EXPERIMENTAL
Intervention: TTO NE + ADA Gel
Number of subjects: 100
Study 34251536 — intervention group
Group type: COMPARATOR
Intervention: ADA Marketed Gel
Number of subjects: 100
Study 34543460 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable collagen membranes (BG)
Number of subjects: 39
Study 34543460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresorbable ePTFE membranes (GT)
Number of subjects: 39
Study 34543460 — intervention group
Group type: COMPARATOR
Intervention: Implants placed in pristine bone (CT)
Number of subjects: 39
Study 35259925 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide-type diuretics
Number of subjects: 9252
Study 35259925 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system blockers
Number of subjects: 9252
Study 35259925 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 9252
Study 35259925 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 9252
Study 35259925 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide-type diuretics and renin-angiotensin system blockers
Number of subjects: 9252
Study 35051663 — intervention group
Group type: EXPERIMENTAL
Intervention: aPDT (antimicrobial photodynamic therapy) using a curcumin-based photosensitizer, exposed to 660 nm light for 5 minutes at 200 J/cm2 fluency.
Number of subjects: 46
Study 35051663 — intervention group
Group type: COMPARATOR
Intervention: Sham aPDT (non-activated laser tip).
Number of subjects: 46
Study 35333743 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (9 to 12 mg/kg)
Number of subjects: 20
Study 35333743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 32197631 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational training for GPs promoting a deprescribing guideline and conducting family conferences.
Number of subjects: 676
Study 32197631 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group).
Number of subjects: 676
Study 34534319 — intervention group
Group type: EXPERIMENTAL
Intervention: Preseason HAI antibody titers
Number of subjects: 5180
Study 34534319 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination
Number of subjects: 5180
Study 35871010 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (ICBT) with pre-treatment assessment interview
Number of subjects: 270
Study 35871010 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (ICBT) with guidance
Number of subjects: 270
Study 35871010 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (ICBT) with both pre-treatment assessment interview and guidance
Number of subjects: 270
Study 35871010 — intervention group
Group type: COMPARATOR
Intervention: Internet-delivered cognitive behavioral therapy (ICBT) with neither pre-treatment assessment interview nor guidance
Number of subjects: 270
Study 32164723 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet- and mobile-based cognitive behavioural therapy (iCBT) in addition to treatment as usual (TAU)
Number of subjects: 212
Study 32164723 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (TAU+)
Number of subjects: 212
Study 32164723 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet- and mobile-based cognitive behavioural therapy (iCBT)
Number of subjects: 212
Study 36404644 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride (SDF) 38% applied for 1 minute
Number of subjects: 356
Study 36404644 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tap water) applied for 1 minute
Number of subjects: 356
Study 32472526 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet and anticoagulant therapies
Number of subjects: 0
Study 32472526 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 0
Study 32472526 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Number of subjects: 0
Study 32472526 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic nihilism
Number of subjects: 0
Study 32750310 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (1-SD increment of 14.8 mm Hg)
Number of subjects: 935
Study 32750310 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (1-SD increment of 10.7 mm Hg)
Number of subjects: 935
Study 34431213 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis mouthwash
Number of subjects: 32
Study 34431213 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash (without propolis)
Number of subjects: 32
Study 35678032 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) 300 mg with fexofenadine 60 mg and pseudoephedrine 120 mg
Number of subjects: 10
Study 35678032 — intervention group
Group type: COMPARATOR
Intervention: Water (control) with fexofenadine 60 mg and pseudoephedrine 120 mg
Number of subjects: 10
Study 35678032 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE)
Number of subjects: 10
Study 33772998 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart speakers (e.g., Amazon Alexa, Google Home) for about 12 weeks
Number of subjects: 43
Study 33772998 — intervention group
Group type: COMPARATOR
Intervention: Control group (no smart speakers)
Number of subjects: 43
Study 32714972 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscles and transverse abdominal muscle training (PFM + TrA, n=70)
Number of subjects: 140
Study 32714972 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscles training alone (PFM, n=70)
Number of subjects: 140
Study 35938217 — intervention group
Group type: EXPERIMENTAL
Intervention: Nail polish
Number of subjects: 885
Study 35938217 — intervention group
Group type: COMPARATOR
Intervention: Polish-free (unpainted nails)
Number of subjects: 885
Study 35236647 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus nab-paclitaxel
Number of subjects: 44
Study 35236647 — intervention group
Group type: COMPARATOR
Intervention: Control: nab-paclitaxel
Number of subjects: 44
Study 34472895 — intervention group
Group type: EXPERIMENTAL
Intervention: SHED-IT: Recharge (self-guided eHealth program)
Number of subjects: 125
Study 34472895 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 125
Study 32913029 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (32°C-34°C for 24 hours) plus standard care
Number of subjects: 270
Study 32913029 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 270
Study 32913029 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >65 years
Number of subjects: 270
Study 32913029 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractory convulsive status epilepticus
Number of subjects: 270
Study 32913029 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary brain insult
Number of subjects: 270
Study 32913029 — intervention group
Group type: EXPERIMENTAL
Intervention: No bystander-witnessed seizure onset
Number of subjects: 270
Study 35674757 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05% lotion
Number of subjects: 29
Study 35674757 — intervention group
Group type: COMPARATOR
Intervention: Vehicle group
Number of subjects: 29
Study 33255353 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet intervention (self-sustained for 6 months)
Number of subjects: 48
Study 33255353 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean Diet intervention (active for 6 months)
Number of subjects: 48
Study 33255353 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet intervention
Number of subjects: 48
Study 32185590 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 0
Study 32185590 — intervention group
Group type: EXPERIMENTAL
Intervention: One trabecular micro-bypass stent
Number of subjects: 0
Study 32185590 — intervention group
Group type: EXPERIMENTAL
Intervention: Two trabecular micro-bypass stents
Number of subjects: 0
Study 32185590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracanalicular scaffold
Number of subjects: 0
Study 32185590 — intervention group
Group type: EXPERIMENTAL
Intervention: Two trabecular micro-bypass stents with cataract surgery
Number of subjects: 0
Study 33220090 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcrestal sinus floor elevation (TSFE) with bovine‐derived xenograft and implant placement
Number of subjects: 41
Study 33220090 — intervention group
Group type: COMPARATOR
Intervention: Lateral sinus floor elevation (LSFE) with bovine‐derived xenograft and implant placement
Number of subjects: 41
Study 35913699 — intervention group
Group type: EXPERIMENTAL
Intervention: VIPP-PRE intervention
Number of subjects: 2
Study 34002326 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR)
Number of subjects: 31
Study 34002326 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR + Electric Muscle Stimulation (EMS)
Number of subjects: 31
Study 34002326 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 31
Study 35387494 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting Tai Chi
Number of subjects: 80
Study 33500356 — intervention group
Group type: EXPERIMENTAL
Intervention: IGV-001
Number of subjects: 33
Study 33500356 — intervention group
Group type: COMPARATOR
Intervention: SOC (standard of care)
Number of subjects: 33
Study 35122614 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical triamcinolone 0.1% ointment
Number of subjects: 28
Study 35122614 — intervention group
Group type: COMPARATOR
Intervention: Topical mechlorethamine/chlormethine gel alone
Number of subjects: 28
Study 36495879 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan 5.4 mg/kg
Number of subjects: 524
Study 36495879 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab emtansine 3.6 mg/kg
Number of subjects: 524
Study 36495879 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 524
Study 36495879 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab emtansine
Number of subjects: 524
Study 33587901 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-blocking spectacles
Number of subjects: 120
Study 33587901 — intervention group
Group type: COMPARATOR
Intervention: Clear (placebo) spectacles
Number of subjects: 120
Study 36471429 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative oral administration of cephalexin and metronidazole
Number of subjects: 210
Study 32576043 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrinologists
Number of subjects: 359
Study 32576043 — intervention group
Group type: COMPARATOR
Intervention: General screening practices
Number of subjects: 359
Study 32576043 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors leading to screening
Number of subjects: 359
Study 32701204 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute CSC
Number of subjects: 80
Study 32701204 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic CSC
Number of subjects: 80
Study 32701204 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 80
Study 32274746 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring balloon angioplasty (SBA) prior to drug-coated balloon angioplasty (DCB)
Number of subjects: 481
Study 33806669 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat acclimation with permissive dehydration (DEH)
Number of subjects: 14
Study 33806669 — intervention group
Group type: COMPARATOR
Intervention: Euhydration (EUH)
Number of subjects: 14
Study 34001097 — intervention group
Group type: EXPERIMENTAL
Intervention: Equilibrator Series II (Eptamed)
Number of subjects: 60
Study 34001097 — intervention group
Group type: COMPARATOR
Intervention: Occlus‐o‐Guide (Sweden & Martina)
Number of subjects: 60
Study 33207242 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transpinal direct current stimulation (tsDCS) combined with language training
Number of subjects: 10
Study 33207242 — intervention group
Group type: COMPARATOR
Intervention: Sham transpinal direct current stimulation (tsDCS)
Number of subjects: 10
Study 33207242 — intervention group
Group type: COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS) combined with the same language treatment
Number of subjects: 10
Study 32779506 — intervention group
Group type: EXPERIMENTAL
Intervention: Illiteracy
Number of subjects: 3861
Study 32779506 — intervention group
Group type: COMPARATOR
Intervention: Lowest education level
Number of subjects: 3861
Study 35277995 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-041
Number of subjects: 0
Study 34153272 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 4806
Study 34153272 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4806
Study 33742271 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based self-regulated training (HSRT)
Number of subjects: 0
Study 33742271 — intervention group
Group type: COMPARATOR
Intervention: Centralized instructor-regulated training (CIRT)
Number of subjects: 0
Study 33742271 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HSRT and CIRT
Number of subjects: 0
Study 34307977 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 741
Study 34307977 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 741
Study 36364764 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine-rich protein powder
Number of subjects: 50
Study 36364764 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 50
Study 36364764 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Leucine-rich protein and Placebo)
Number of subjects: 50
Study 34684498 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium high-potassium seasonings and processed foods
Number of subjects: 187
Study 34684498 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard sodium and potassium content)
Number of subjects: 187
Study 32215674 — intervention group
Group type: EXPERIMENTAL
Intervention: r-ESWT (2000 pulses of shockwave at 2.0 to 3.0 bar weekly for three weeks)
Number of subjects: 104
Study 32215674 — intervention group
Group type: COMPARATOR
Intervention: sham-ESWT
Number of subjects: 104
Study 36372069 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dapagliflozin
Number of subjects: 6263
Study 36372069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6263
Study 32470486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib plus standard-of-care treatment
Number of subjects: 41
Study 32470486 — intervention group
Group type: COMPARATOR
Intervention: Placebo based on standard-of-care treatment
Number of subjects: 41
Study 32470486 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 34468591 — intervention group
Group type: EXPERIMENTAL
Intervention: Split Workout Routine (n=35)
Number of subjects: 67
Study 34468591 — intervention group
Group type: COMPARATOR
Intervention: Full-Body Workout Routine (n=32)
Number of subjects: 67
Study 32032137 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine inhalers
Number of subjects: 310
Study 32032137 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 310
Study 32032137 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 310
Study 34280363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 623
Study 34280363 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cataract surgery)
Number of subjects: 623
Study 33290975 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based radiomics features for LNM prediction
Number of subjects: 163
Study 33290975 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based radiomics features for VEGF prediction
Number of subjects: 163
Study 35396709 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 93
Study 35396709 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 93
Study 34110707 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin (AX)
Number of subjects: 42
Study 34110707 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 42
Study 36400597 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (125 mg orally daily)
Number of subjects: 24
Study 36400597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 34313697 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic hydrocortisone treatment initiated 7 to 14 days after birth
Number of subjects: 0
Study 34313697 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32217498 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based TSN app prototype
Number of subjects: 299
Study 32217498 — intervention group
Group type: COMPARATOR
Intervention: Conventional self-managing control group
Number of subjects: 299
Study 36104443 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alfacalcidol
Number of subjects: 976
Study 36104443 — intervention group
Group type: COMPARATOR
Intervention: No vitamin D receptor activators
Number of subjects: 976
Study 33144157 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher adiponectin levels (per 5-µg/ml increase)
Number of subjects: 1641
Study 33009898 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct anterior approach
Number of subjects: 55
Study 33009898 — intervention group
Group type: COMPARATOR
Intervention: Posterior approach
Number of subjects: 55
Study 33009898 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 55
Study 35896688 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused low‐intensity pulsed ultrasound (FLIPUS)
Number of subjects: 114
Study 35896688 — intervention group
Group type: COMPARATOR
Intervention: Pulsed shortwave diathermy (PSWD)
Number of subjects: 114
Study 35807858 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL of carbonated water plus two kiwifruit (intervention)
Number of subjects: 43
Study 35807858 — intervention group
Group type: COMPARATOR
Intervention: 500 mL of carbonated water (control)
Number of subjects: 43
Study 32627264 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact force–guided radiofrequency (CF‐RF) ablation
Number of subjects: 346
Study 32627264 — intervention group
Group type: COMPARATOR
Intervention: Cryoballoon ablation
Number of subjects: 346
Study 35914738 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component, system-level intervention including parent reminders, provider training, clinic-level audit and feedback, workflow modifications
Number of subjects: 15000
Study 35914738 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component, system-level intervention
Number of subjects: 15000
Study 35914738 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 15000
Study 33356730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of aspirin at 1 month with continued ticagrelor monotherapy for 23 months
Number of subjects: 0
Study 33356730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of ticagrelor at 12 months
Number of subjects: 0
Study 33356730 — intervention group
Group type: COMPARATOR
Intervention: TRAP-induced PA
Number of subjects: 0
Study 32538550 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla‐300)
Number of subjects: 3304
Study 32538550 — intervention group
Group type: COMPARATOR
Intervention: Standard‐of‐care basal insulin analogues (SOC‐BI)
Number of subjects: 3304
Study 35504634 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary interruption of low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster
Number of subjects: 560
Study 35504634 — intervention group
Group type: COMPARATOR
Intervention: Usual care (continuing low-dose methotrexate treatment)
Number of subjects: 560
Study 35504634 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary interruption of low-dose methotrexate treatment
Number of subjects: 560
Study 33914964 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11+ Referees Program
Number of subjects: 200
Study 33914964 — intervention group
Group type: COMPARATOR
Intervention: Usual warm-ups (Control)
Number of subjects: 200
Study 91276441 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg twice a day for three weeks)
Number of subjects: 30
Study 91276441 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 35835920 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (extracorporeal interrupted 0 delayed absorbable sutures)
Number of subjects: 80
Study 35835920 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (U-shaped running locked 0 delayed absorbable suture)
Number of subjects: 80
Study 35835920 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 80
Study 33012083 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus plus Sirolimus (Tac/Sir)
Number of subjects: 141